Revolution Medicines Inc (RVMD) - Total Assets
Based on the latest financial reports, Revolution Medicines Inc (RVMD) holds total assets worth $2.25 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Revolution Medicines Inc shareholders equity for net asset value and shareholders' equity analysis.
Revolution Medicines Inc - Total Assets Trend (2017–2024)
This chart illustrates how Revolution Medicines Inc's total assets have evolved over time, based on quarterly financial data.
Revolution Medicines Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Revolution Medicines Inc's total assets of $2.25 Billion consist of 91.0% current assets and 9.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 21.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $56.67 Million | 2.2% |
| Goodwill | $14.61 Million | 0.6% |
Asset Composition Trend (2017–2024)
This chart illustrates how Revolution Medicines Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see RVMD company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Revolution Medicines Inc's current assets represent 91.0% of total assets in 2024, an increase from 62.6% in 2017.
- Cash Position: Cash and equivalents constituted 21.2% of total assets in 2024, down from 60.2% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is intangible assets at 2.2% of total assets.
Revolution Medicines Inc Competitors by Total Assets
Key competitors of Revolution Medicines Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Revolution Medicines Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.05 | 14.24 | 9.63 |
| Quick Ratio | 8.05 | 14.24 | 9.63 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.73 Billion | $1.47 Billion | $406.95 Million |
Revolution Medicines Inc - Advanced Valuation Insights
This section examines the relationship between Revolution Medicines Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.67 |
| Latest Market Cap to Assets Ratio | 7.28 |
| Asset Growth Rate (YoY) | 24.1% |
| Total Assets | $2.56 Billion |
| Market Capitalization | $18.62 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Revolution Medicines Inc's assets at a significant premium (7.28x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Revolution Medicines Inc's assets grew by 24.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Revolution Medicines Inc (2017–2024)
The table below shows the annual total assets of Revolution Medicines Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $2.56 Billion | +24.09% |
| 2023-12-31 | $2.06 Billion | +153.93% |
| 2022-12-31 | $811.93 Million | +10.02% |
| 2021-12-31 | $737.99 Million | +30.06% |
| 2020-12-31 | $567.40 Million | +157.29% |
| 2019-12-31 | $220.53 Million | +29.28% |
| 2018-12-31 | $170.59 Million | +1031.43% |
| 2017-12-31 | $15.08 Million | -- |
About Revolution Medicines Inc
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS comp… Read more